Precigen Secures Historic FDA Approval for PAPZIMEOS- First and Only Therapy for Adult RRP Patients

August 15, 2025

DENVER, Colo., Aug 15, 2025 (247marketnews.com)- Precigen (NASDAQ:PGEN) stated that the U.S. Food and Drug Administration (FDA) granted full approval for PAPZIMEOS, the first and only approved therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP).

The approval is not conditional and does not require a confirmatory trial, marking a definitive regulatory win for both Precigen and the RRP patient community. PAPZIMEOS is designed to address the root cause of RRP, chronic HPV 6 or 11 infection, by generating a targeted immune response using a non-replicating adenoviral vector-based immunotherapy.

” For more than a century, since RRP was first recognized as a distinct disease, patients have had to rely on repeated surgeries to manage this relentless condition,” commented Helen Sabzevari, PhD, President and CEO of Precigen. “With the landmark FDA approval of PAPZIMEOS and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease.”

RRP is a rare but debilitating condition, impacting an estimated 27,000 adults in the U.S. Patients suffer from benign tumors in the airway, leading to chronic surgeries, severe voice disturbances, and increased respiratory risk. Until now, no FDA-approved therapies existed.

PAPZIMEOS is delivered through four subcutaneous injections over a 12-week period.

Landmark Clinical Results

Approval is based on a pivotal open-label study conducted at the National Institutes of Health:

  • 51% of patients (18 of 35) achieved a Complete Response—no surgeries required for at least 12 months post-treatment
  • Responses were durable with 15 of 18 patients maintaining surgical remission at 24 months
  • The therapy was well-tolerated, with no dose-limiting toxicities or treatment-related events above Grade 2
  • PAPZIMEOS induced HPV 6/11-specific T cell responses, especially in patients who responded to treatment

“This long-awaited FDA approval represents a momentous milestone for the RRP community,” added Kim McClellan, President of the RRP Foundation. “For the first time, adult patients with RRP have access to an FDA-approved therapy that offers the potential to reduce—or even eliminate—endless repeated surgeries.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PGEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.